Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its prostate cancer treatment previously marketed under the generic name degarelix. Firmagon is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist that provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth. It is available in 80mg and 120mg vials of powder for reconstitution.

For more information call (888) FERRING or visit www.ferringusa.com.